Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00440388
Status:
COMPLETED
Last Update Posted:
2010-08-27
First Post:
2007-02-23
Brief Title:
Safety Efficacy Study of AT-101 in Combination w Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkins Lymphoma
Sponsor:
Ascenta Therapeutics
Organization:
Ascenta Therapeutics
Study Overview
Official Title:
An Open-label Multicenter Phase II Study of AT-101 in Combination With Rituximab in Patients With Untreated Grade I-II Follicular Non-Hodgkins Lymphoma
Status:
COMPLETED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase II clinical trial in patients who have not received systemic treatment for follicular non-Hodgkins lymphoma The study combines rituximab an approved drug for this disease with AT-101 an experimental drug The hypothesis is that by adding AT-101 to the rituximab regimen improvement to patients response to the treatment will be observed verses rituximab alone
Detailed Description:
Further Study Details provided by Ascenta
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None